An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1, 2011, Pages 149-153

  De Laat, B ^a,b   Derksen, R H W M ^a   Reber, G ^c   Musial, J ^d   Swadzba, J ^d   Bozic, B ^e   Cucnik, S ^e   Regnault, V ^f   Forastiero, R ^g   Woodhams, B J ^h   De Groot, P H G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f INSERM   (France)

^g HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^h Serbio Diagnostica Stago   (France)

Author keywords

Antiphospholipid; Beta2 glycoprotein I; Lupus anticoagulant; Pregnancy morbidity; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CALCIUM; CITRATE SODIUM; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; ANALYTIC METHOD; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING TIME; CHILD; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LUPUS ANTICOAGULANT ASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ARGENTINA; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; BLOOD SPECIMEN COLLECTION; CHILD; CITRATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; HUMANS; LOGISTIC MODELS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; ODDS RATIO; PARTIAL THROMBOPLASTIN TIME; REAGENT KITS, DIAGNOSTIC; THROMBOSIS; YOUNG ADULT;

EID: 78650963444     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04068.x     Document Type: Article

References (17)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295.
3. Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499.
4. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 26: 1211.
5. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-glycoprotein I (Apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120.
6. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827.
7. Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol 2000; 12: 374.
8. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717.
9. Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740.
10. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598.
11. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 10: 1737-40.
12. Le Querrec A, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, Delahousse B, Reber G, Sié P. Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001; 86: 584-9.
13. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702.
14. de Groot PG, Derksen RH. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis. 2005; 18: 205.
15. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94: 665-72.
16. Fernández JA, Kojima K, Petäjä J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis 2000; 26: 115-23.
17. de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19: 757-64.